Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668521 · ClinicalTrials.gov registry record
Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection
A clinical trial, sponsored by Aspira Women's Health.
- Terminated
- Registry status
- 215
- Enrollment target
NCT04668521 is a clinical trial that was terminated before completion, run by Aspira Women's Health. The registered enrollment target is 215 participants.
The verdict
NCT04668521 was terminated before completion, sponsored by Aspira Women's Health.
- TERMINATED
- Registry status
- 215 participants
- Enrollment target
Study Summary
The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.
Interventions
- OTHER OVA360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2020-05-04 |
| Est. Completion | 2023-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04668521
The ClinicalTrials.gov registry entry for NCT04668521 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aspira Women's Health, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OVA360 is the first listed.
NCT04668521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04668521 about?
NCT04668521 is a clinical study titled "Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection". The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.
What is the current status of trial NCT04668521?
This trial is currently terminated. The enrollment target is 215 participants. The study started on 2020-05-04. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT04668521?
The interventions under investigation include: OVA360 (OTHER).
Who is sponsoring clinical trial NCT04668521?
This trial is sponsored by Aspira Women's Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.